Clinical Study of AFN50 Injection in the Autoimmune Diseases

Sponsor
AlphaNa Bioscience Company Limited
Study ID
NCT07408336
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmune Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 69 Years
Healthy Volunteers
Not accepted

Interventions

  • AFN50 injection — BIOLOGICAL
    Intravenous infusion therapy. AFN50 was developed using novel T-cell-targeted lipid nanoparticles (T-LNP) encapsulating mRNA encoding Chimeric Antigen Receptor.

Study Details

This is an investigator-initiated trial designed to evaluate the safety, tolerability and primary efficacy of AFN50 injection for the treatment of autoimmune diseases.

Key Dates

First listed
Feb 13, 2026
Start date
Feb 4, 2026
Status verified
Mar 2026
Primary completion
Feb 4, 2028
Completion
Feb 3, 2029

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Participant Group
    AFN50 Injection

Primary Outcome Measure

Adverse events [ Time Frame: 3 months ]

Central Contacts

Related Studies